Dr. Pollack on the Future Treatment Landscape for Sarcoma

Seth M. Pollack, MD
Published: Friday, Apr 07, 2017



Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the future treatment paradigm of soft tissue sarcoma.

Regarding radiomics, Pollack envisions this novel treatment approach will have a role in the future.

Additionally, Pollack says that he is very excited for the field of sarcoma to move toward immunotherapy in the next 5 to 10 years. The data from SARC028, which investigated treatment with the PD-1 inhibitor pembrolizumab (Keytruda) holds promise for patients with pleomorphic undifferentiated sarcoma. Another ongoing clinical trial is exploring the combination trial of doxorubicin plus pembrolizumab, which also is exciting, Pollack adds.


Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the future treatment paradigm of soft tissue sarcoma.

Regarding radiomics, Pollack envisions this novel treatment approach will have a role in the future.

Additionally, Pollack says that he is very excited for the field of sarcoma to move toward immunotherapy in the next 5 to 10 years. The data from SARC028, which investigated treatment with the PD-1 inhibitor pembrolizumab (Keytruda) holds promise for patients with pleomorphic undifferentiated sarcoma. Another ongoing clinical trial is exploring the combination trial of doxorubicin plus pembrolizumab, which also is exciting, Pollack adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x